Revenio Group Oyj · OMXHEX:REG1V
Revenio Group Oyj — Q2 2026 Earnings Presentation
22 slides from Revenio Group Oyj's earnings presentation, Sep 8, 2026
Slide 1: Q2/2026 Half-year report
Q2/2026 HALF-YEAR REPORT Q2/2026 Half-year report 1 8.9.2026 Revenio
Slide 2: Disclaimer
Q2/2026 HALF-YEAR REPORT Disclaimer This presentation does not constitute an invitation to underwrite, subscribe for, or otherwise acquire or dispose of any Revenio Group Corporation’s shares. Group's past performance is no guide to future performance, and persons needing advice should consult an in
Slide 3: Today's presenters
Q2/2026 HALF-YEAR REPORT Today’s presenters Jouni Jukka Toijala Kainulainen CEO CFO 3 8.9.2026 Revenio
Slide 4: Agenda
Q2/2026 HALF-YEAR REPORT Agenda 1. Visionix integration and synergy target status 2. Highlights of Q2/2026 3. Financials of Q2/2026 4. Financial guidance for 2026 5. Q&A 4 8.9.2026 Revenio
Slide 5: Building the new Revenio progressing according to plan
Building the new Revenio progressing according to plan • In May 2026, Revenio joined forces with Visionix, serving eye care professionals across optometry, optical retail and ophthalmology with complementary product portfolio • 2.5x increase in addressable market to more than 2.5b€ covering the enti
Slide 6: Visionix integration progressing well
Q2/2026 HALF-YEAR REPORT Visionix integration progressing well 1 Integration on track 2 Commercial activation • US sales organization in place and cross- • Business continuity and customer training started relationships maintained • Strategic account-level cross-selling planning €5m • Leadership, go
Slide 7: April-June highlights
Q2/2026 HALF-YEAR REPORT April-June highlights • Visionix has been included in the Group figures since the beginning of June Net sales EBIT • Net sales totaled EUR 39.3 (26.5) million, up by 48.1% 39.3 2.4 • The currency-adjusted increase in net sales was MEUR (+48.1%) MEUR (-60.9%) 50.7% • Operatin
Slide 8: January-June highlights
Q2/2026 HALF-YEAR REPORT January-June highlights • Net sales totaled EUR 66.6 (52.6) million, up by 26.6% Net sales EBIT • The currency-adjusted growth of net sales was 28.8% 66.6 4.8 MEUR (+26.6%) MEUR (-62.4%) • Operating profit was EUR 4.8 (12.7) million, affected by non-recurring expenses arisin
Slide 9: iHealthScreen and iCare DRSplus FDA clearance
Q2/2026 HALF-YEAR REPORT iHealthScreen and iCare DRSplus FDA clearance iCare DRSplus included in FDA-cleared AI solution for diabetic retinopathy screening The U.S.-based health technology company iHealthScreen has received FDA clearance for its iPredict-DR AI software Software analyzes images captu
Slide 10: EyeCheq strategic partnership
Q2/2026 HALF-YEAR REPORT EyeCheq strategic partnership iCare and EyeCheq announced in August a strategic partnership and minority investment EyeCheq stations integrate the iCare DRSplus fundus imaging device The aim is to accelerate the adoption and accessibility of automated screening solutions and
Slide 11: Financials Q2/2026
Q2/2026 HALF-YEAR REPORT Financials Q2/2026 11 8.9.2026 Revenio
Slide 12: Key figures Q2/2026
Q2/2026 HALF-YEAR REPORT Key figures Q2/2026 MEUR 4-6/2026 4-6/2025 Change 1-6/ 1-6/ Change -% 2026 2025 -% • Q2 net sales increased 48.1% to Net sales 39.3 26.5 48.1 66.6 52.6 26.6 EUR 39.3 million (26.5 million), Gross margin 25.4 19.3 31.8 44.1 38.2 15.4 with Visionix consolidated from Gross marg
Slide 13: Net sales increased following Visionix consolidation
Q2/2026 HALF-YEAR REPORT Net sales increased following Visionix consolidation • Q2 net sales were EUR 39.3 Net sales (EUR million) million, up 48.1% year on year. 45 39,3 • Visionix contributed to Group 40 figures from the beginning of 35 June. 30,5 31,2 30 29,1 • Underlying Revenio net sales 26,5 2
Slide 14: Profitability impacted by gross margin and cost base
Q2/2026 HALF-YEAR REPORT Profitability impacted by gross margin and cost base Adjusted operating profit EUR million and % (EBIT) • Adjusted operating profit was EUR 10 9,5 35 5.8 million, or 14.6% of net sales, 9,3 compared with EUR 6.6 million 9 30 and 24.7% a year earlier. 8 7,2 • Gross margin dec
Slide 15: Cash flow from operations
Q2/2026 HALF-YEAR REPORT Cash flow from operations Cash flow from operations (EUR million) • Q2 cash flow from operations 20 was EUR -2.4 million (EUR +6.7 million). Q2 cash flow included 15,9 a negative EUR 3.0 million 15 impact from integration payments and increased working capital. 9,8 10 • H1 c
Slide 16: Balance sheet reflects acquisition financing
Q2/2026 HALF-YEAR REPORT Balance sheet reflects acquisition financing Equity ratio and net gearing (%) • Net debt was EUR 237.9 90 180 million at the end of June 80,2 77,2 79,6 79,1 160 following completion of the 80 76,3 76,2 76,1 71,1 72,2 72,7 74,5 74,7 140 Visionix acquisition. 70 120 • In addit
Slide 17: Shareholders on June 30, 2026
Q2/2026 HALF-YEAR REPORT Shareholders on June 30, 2026* No. of shares % Verified Ownership 1. William Demant Invest A/S 6,657,461 22.83% 2029-06-30 2. Caravelle Capital SAS 1,522,754 5.22% 2026-05-29 3. Danske Invest 850,818 2.92% 2026-06-30 4. Vanguard 836,839 2.87% 2026-06-30 5. SEB Funds 724,815
Slide 18: Financial guidance for 2026
Q2/2026 HALF-YEAR REPORT Financial guidance for 2026 New Financial Guidance Revenio Group’s exchange rate-adjusted net sales are estimated to be between EUR 190 million and EUR 205 million and EBITA, excluding non-recurring items, is estimated to remain at a satisfactory level. The lower end of the
Slide 19: Capital Markets Day September 15
Q2/2026 HALF-YEAR REPORT Capital Markets Day September 15 At our Capital Markets Day later in September, we will present our new strategy and provide more detail on our long-term targets and on how we intend to leverage the growth opportunities offered by our expanded product portfolio, global prese
Slide 20: Post-completion rights issue
Q2/2026 HALF-YEAR REPORT Post-completion rights issue Revenio plans to execute a EUR 80 million post-completion rights issue Nordea has been engaged to act as the global coordinator and underwriter for the rights issue • Targeted to be arranged during mid to late H2/2026 • William Demant Invest, own
Slide 21: Q&A
Q2/2026 HALF-YEAR REPORT Q&A 21 8.9.2026 Revenio
Slide 22: Revenio
REVENIO